- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Follicular Lymphoma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Follicular Lymphoma Treatment market size is estimated to be worth US$ 1730.4 million in 2021 and is forecast to a readjusted size of USD 2640 million by 2028 with a CAGR of 6.2% during review period. Hospital accounting for % of the Follicular Lymphoma Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Chemotherapy segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Follicular Lymphoma Treatment include Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Inc., and Celltrion, Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Follicular Lymphoma Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chemotherapy
Radiotherapy
Monoclonal Antibodies
Stem Cell Transplantation
Market segment by Application, can be divided into
Hospital
Clinic
Others
Market segment by players, this report covers
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Curis, Inc.
Dynavax Technologies Corporation
Eisai
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Immune Design Corp.
ImmunoGen, Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Follicular Lymphoma Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Follicular Lymphoma Treatment, with revenue, gross margin and global market share of Follicular Lymphoma Treatment from 2019 to 2022.
Chapter 3, the Follicular Lymphoma Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Follicular Lymphoma Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Follicular Lymphoma Treatment research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Follicular Lymphoma Treatment
1.2 Classification of Follicular Lymphoma Treatment by Type
1.2.1 Overview: Global Follicular Lymphoma Treatment Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Follicular Lymphoma Treatment Revenue Market Share by Type in 2021
1.2.3 Chemotherapy
1.2.4 Radiotherapy
1.2.5 Monoclonal Antibodies
1.2.6 Stem Cell Transplantation
1.3 Global Follicular Lymphoma Treatment Market by Application
1.3.1 Overview: Global Follicular Lymphoma Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Follicular Lymphoma Treatment Market Size & Forecast
1.5 Global Follicular Lymphoma Treatment Market Size and Forecast by Region
1.5.1 Global Follicular Lymphoma Treatment Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Follicular Lymphoma Treatment Market Size by Region, (2017-2022)
1.5.3 North America Follicular Lymphoma Treatment Market Size and Prospect (2017-2028)
1.5.4 Europe Follicular Lymphoma Treatment Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Follicular Lymphoma Treatment Market Size and Prospect (2017-2028)
1.5.6 South America Follicular Lymphoma Treatment Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Follicular Lymphoma Treatment Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Follicular Lymphoma Treatment Market Drivers
1.6.2 Follicular Lymphoma Treatment Market Restraints
1.6.3 Follicular Lymphoma Treatment Trends Analysis
2 Company Profiles
2.1 Boehringer Ingelheim GmbH
2.1.1 Boehringer Ingelheim GmbH Details
2.1.2 Boehringer Ingelheim GmbH Major Business
2.1.3 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Product and Solutions
2.1.4 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business
2.2.3 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Product and Solutions
2.2.4 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.3 Celgene Corporation
2.3.1 Celgene Corporation Details
2.3.2 Celgene Corporation Major Business
2.3.3 Celgene Corporation Follicular Lymphoma Treatment Product and Solutions
2.3.4 Celgene Corporation Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Celgene Corporation Recent Developments and Future Plans
2.4 Celldex Therapeutics, Inc.
2.4.1 Celldex Therapeutics, Inc. Details
2.4.2 Celldex Therapeutics, Inc. Major Business
2.4.3 Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Product and Solutions
2.4.4 Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Celldex Therapeutics, Inc. Recent Developments and Future Plans
2.5 Celltrion, Inc.
2.5.1 Celltrion, Inc. Details
2.5.2 Celltrion, Inc. Major Business
2.5.3 Celltrion, Inc. Follicular Lymphoma Treatment Product and Solutions
2.5.4 Celltrion, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Celltrion, Inc. Recent Developments and Future Plans
2.6 Cellular Biomedicine Group, Inc.
2.6.1 Cellular Biomedicine Group, Inc. Details
2.6.2 Cellular Biomedicine Group, Inc. Major Business
2.6.3 Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Product and Solutions
2.6.4 Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Cellular Biomedicine Group, Inc. Recent Developments and Future Plans
2.7 Coherus BioSciences, Inc.
2.7.1 Coherus BioSciences, Inc. Details
2.7.2 Coherus BioSciences, Inc. Major Business
2.7.3 Coherus BioSciences, Inc. Follicular Lymphoma Treatment Product and Solutions
2.7.4 Coherus BioSciences, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Coherus BioSciences, Inc. Recent Developments and Future Plans
2.8 CTI BioPharma Corp.
2.8.1 CTI BioPharma Corp. Details
2.8.2 CTI BioPharma Corp. Major Business
2.8.3 CTI BioPharma Corp. Follicular Lymphoma Treatment Product and Solutions
2.8.4 CTI BioPharma Corp. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 CTI BioPharma Corp. Recent Developments and Future Plans
2.9 Curis, Inc.
2.9.1 Curis, Inc. Details
2.9.2 Curis, Inc. Major Business
2.9.3 Curis, Inc. Follicular Lymphoma Treatment Product and Solutions
2.9.4 Curis, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Curis, Inc. Recent Developments and Future Plans
2.10 Dynavax Technologies Corporation
2.10.1 Dynavax Technologies Corporation Details
2.10.2 Dynavax Technologies Corporation Major Business
2.10.3 Dynavax Technologies Corporation Follicular Lymphoma Treatment Product and Solutions
2.10.4 Dynavax Technologies Corporation Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Dynavax Technologies Corporation Recent Developments and Future Plans
2.11 Eisai
2.11.1 Eisai Details
2.11.2 Eisai Major Business
2.11.3 Eisai Follicular Lymphoma Treatment Product and Solutions
2.11.4 Eisai Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Eisai Recent Developments and Future Plans
2.12 EpiZyme, Inc.
2.12.1 EpiZyme, Inc. Details
2.12.2 EpiZyme, Inc. Major Business
2.12.3 EpiZyme, Inc. Follicular Lymphoma Treatment Product and Solutions
2.12.4 EpiZyme, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 EpiZyme, Inc. Recent Developments and Future Plans
2.13 F. Hoffmann-La Roche Ltd.
2.13.1 F. Hoffmann-La Roche Ltd. Details
2.13.2 F. Hoffmann-La Roche Ltd. Major Business
2.13.3 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Product and Solutions
2.13.4 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.14 Genentech, Inc.
2.14.1 Genentech, Inc. Details
2.14.2 Genentech, Inc. Major Business
2.14.3 Genentech, Inc. Follicular Lymphoma Treatment Product and Solutions
2.14.4 Genentech, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Genentech, Inc. Recent Developments and Future Plans
2.15 Gilead Sciences, Inc.
2.15.1 Gilead Sciences, Inc. Details
2.15.2 Gilead Sciences, Inc. Major Business
2.15.3 Gilead Sciences, Inc. Follicular Lymphoma Treatment Product and Solutions
2.15.4 Gilead Sciences, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Gilead Sciences, Inc. Recent Developments and Future Plans
2.16 GlaxoSmithKline Plc
2.16.1 GlaxoSmithKline Plc Details
2.16.2 GlaxoSmithKline Plc Major Business
2.16.3 GlaxoSmithKline Plc Follicular Lymphoma Treatment Product and Solutions
2.16.4 GlaxoSmithKline Plc Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 GlaxoSmithKline Plc Recent Developments and Future Plans
2.17 Hutchison MediPharma Limited
2.17.1 Hutchison MediPharma Limited Details
2.17.2 Hutchison MediPharma Limited Major Business
2.17.3 Hutchison MediPharma Limited Follicular Lymphoma Treatment Product and Solutions
2.17.4 Hutchison MediPharma Limited Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Hutchison MediPharma Limited Recent Developments and Future Plans
2.18 Immune Design Corp.
2.18.1 Immune Design Corp. Details
2.18.2 Immune Design Corp. Major Business
2.18.3 Immune Design Corp. Follicular Lymphoma Treatment Product and Solutions
2.18.4 Immune Design Corp. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Immune Design Corp. Recent Developments and Future Plans
2.19 ImmunoGen, Inc.
2.19.1 ImmunoGen, Inc. Details
2.19.2 ImmunoGen, Inc. Major Business
2.19.3 ImmunoGen, Inc. Follicular Lymphoma Treatment Product and Solutions
2.19.4 ImmunoGen, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 ImmunoGen, Inc. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Follicular Lymphoma Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Follicular Lymphoma Treatment Players Market Share in 2021
3.2.2 Top 10 Follicular Lymphoma Treatment Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Follicular Lymphoma Treatment Players Head Office, Products and Services Provided
3.4 Follicular Lymphoma Treatment Mergers & Acquisitions
3.5 Follicular Lymphoma Treatment New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Follicular Lymphoma Treatment Revenue and Market Share by Type (2017-2022)
4.2 Global Follicular Lymphoma Treatment Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Follicular Lymphoma Treatment Revenue Market Share by Application (2017-2022)
5.2 Global Follicular Lymphoma Treatment Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Follicular Lymphoma Treatment Revenue by Type (2017-2028)
6.2 North America Follicular Lymphoma Treatment Revenue by Application (2017-2028)
6.3 North America Follicular Lymphoma Treatment Market Size by Country
6.3.1 North America Follicular Lymphoma Treatment Revenue by Country (2017-2028)
6.3.2 United States Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
6.3.3 Canada Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
6.3.4 Mexico Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Follicular Lymphoma Treatment Revenue by Type (2017-2028)
7.2 Europe Follicular Lymphoma Treatment Revenue by Application (2017-2028)
7.3 Europe Follicular Lymphoma Treatment Market Size by Country
7.3.1 Europe Follicular Lymphoma Treatment Revenue by Country (2017-2028)
7.3.2 Germany Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
7.3.3 France Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
7.3.5 Russia Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
7.3.6 Italy Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Follicular Lymphoma Treatment Revenue by Type (2017-2028)
8.2 Asia-Pacific Follicular Lymphoma Treatment Revenue by Application (2017-2028)
8.3 Asia-Pacific Follicular Lymphoma Treatment Market Size by Region
8.3.1 Asia-Pacific Follicular Lymphoma Treatment Revenue by Region (2017-2028)
8.3.2 China Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
8.3.3 Japan Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
8.3.4 South Korea Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
8.3.5 India Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
8.3.7 Australia Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Follicular Lymphoma Treatment Revenue by Type (2017-2028)
9.2 South America Follicular Lymphoma Treatment Revenue by Application (2017-2028)
9.3 South America Follicular Lymphoma Treatment Market Size by Country
9.3.1 South America Follicular Lymphoma Treatment Revenue by Country (2017-2028)
9.3.2 Brazil Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
9.3.3 Argentina Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Follicular Lymphoma Treatment Revenue by Type (2017-2028)
10.2 Middle East & Africa Follicular Lymphoma Treatment Revenue by Application (2017-2028)
10.3 Middle East & Africa Follicular Lymphoma Treatment Market Size by Country
10.3.1 Middle East & Africa Follicular Lymphoma Treatment Revenue by Country (2017-2028)
10.3.2 Turkey Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
10.3.4 UAE Follicular Lymphoma Treatment Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Follicular Lymphoma Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Follicular Lymphoma Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Follicular Lymphoma Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Follicular Lymphoma Treatment Revenue (USD Million) by Region (2017-2022)
Table 5. Global Follicular Lymphoma Treatment Revenue Market Share by Region (2023-2028)
Table 6. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors
Table 7. Boehringer Ingelheim GmbH Major Business
Table 8. Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Product and Solutions
Table 9. Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Company Major Business
Table 12. Bristol-Myers Squibb Company Follicular Lymphoma Treatment Product and Solutions
Table 13. Bristol-Myers Squibb Company Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Celgene Corporation Corporate Information, Head Office, and Major Competitors
Table 15. Celgene Corporation Major Business
Table 16. Celgene Corporation Follicular Lymphoma Treatment Product and Solutions
Table 17. Celgene Corporation Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Celldex Therapeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 19. Celldex Therapeutics, Inc. Major Business
Table 20. Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Product and Solutions
Table 21. Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Celltrion, Inc. Corporate Information, Head Office, and Major Competitors
Table 23. Celltrion, Inc. Major Business
Table 24. Celltrion, Inc. Follicular Lymphoma Treatment Product and Solutions
Table 25. Celltrion, Inc. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Cellular Biomedicine Group, Inc. Corporate Information, Head Office, and Major Competitors
Table 27. Cellular Biomedicine Group, Inc. Major Business
Table 28. Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Product and Solutions
Table 29. Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Coherus BioSciences, Inc. Corporate Information, Head Office, and Major Competitors
Table 31. Coherus BioSciences, Inc. Major Business
Table 32. Coherus BioSciences, Inc. Follicular Lymphoma Treatment Product and Solutions
Table 33. Coherus BioSciences, Inc. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. CTI BioPharma Corp. Corporate Information, Head Office, and Major Competitors
Table 35. CTI BioPharma Corp. Major Business
Table 36. CTI BioPharma Corp. Follicular Lymphoma Treatment Product and Solutions
Table 37. CTI BioPharma Corp. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Curis, Inc. Corporate Information, Head Office, and Major Competitors
Table 39. Curis, Inc. Major Business
Table 40. Curis, Inc. Follicular Lymphoma Treatment Product and Solutions
Table 41. Curis, Inc. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Dynavax Technologies Corporation Corporate Information, Head Office, and Major Competitors
Table 43. Dynavax Technologies Corporation Major Business
Table 44. Dynavax Technologies Corporation Follicular Lymphoma Treatment Product and Solutions
Table 45. Dynavax Technologies Corporation Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Eisai Corporate Information, Head Office, and Major Competitors
Table 47. Eisai Major Business
Table 48. Eisai Follicular Lymphoma Treatment Product and Solutions
Table 49. Eisai Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. EpiZyme, Inc. Corporate Information, Head Office, and Major Competitors
Table 51. EpiZyme, Inc. Major Business
Table 52. EpiZyme, Inc. Follicular Lymphoma Treatment Product and Solutions
Table 53. EpiZyme, Inc. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. F. Hoffmann-La Roche Ltd. Corporate Information, Head Office, and Major Competitors
Table 55. F. Hoffmann-La Roche Ltd. Major Business
Table 56. F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Product and Solutions
Table 57. F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Genentech, Inc. Corporate Information, Head Office, and Major Competitors
Table 59. Genentech, Inc. Major Business
Table 60. Genentech, Inc. Follicular Lymphoma Treatment Product and Solutions
Table 61. Genentech, Inc. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Gilead Sciences, Inc. Corporate Information, Head Office, and Major Competitors
Table 63. Gilead Sciences, Inc. Major Business
Table 64. Gilead Sciences, Inc. Follicular Lymphoma Treatment Product and Solutions
Table 65. Gilead Sciences, Inc. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. GlaxoSmithKline Plc Corporate Information, Head Office, and Major Competitors
Table 67. GlaxoSmithKline Plc Major Business
Table 68. GlaxoSmithKline Plc Follicular Lymphoma Treatment Product and Solutions
Table 69. GlaxoSmithKline Plc Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Hutchison MediPharma Limited Corporate Information, Head Office, and Major Competitors
Table 71. Hutchison MediPharma Limited Major Business
Table 72. Hutchison MediPharma Limited Follicular Lymphoma Treatment Product and Solutions
Table 73. Hutchison MediPharma Limited Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Immune Design Corp. Corporate Information, Head Office, and Major Competitors
Table 75. Immune Design Corp. Major Business
Table 76. Immune Design Corp. Follicular Lymphoma Treatment Product and Solutions
Table 77. Immune Design Corp. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. ImmunoGen, Inc. Corporate Information, Head Office, and Major Competitors
Table 79. ImmunoGen, Inc. Major Business
Table 80. ImmunoGen, Inc. Follicular Lymphoma Treatment Product and Solutions
Table 81. ImmunoGen, Inc. Follicular Lymphoma Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Global Follicular Lymphoma Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 83. Global Follicular Lymphoma Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 84. Breakdown of Follicular Lymphoma Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 85. Follicular Lymphoma Treatment Players Head Office, Products and Services Provided
Table 86. Follicular Lymphoma Treatment Mergers & Acquisitions in the Past Five Years
Table 87. Follicular Lymphoma Treatment New Entrants and Expansion Plans
Table 88. Global Follicular Lymphoma Treatment Revenue (USD Million) by Type (2017-2022)
Table 89. Global Follicular Lymphoma Treatment Revenue Share by Type (2017-2022)
Table 90. Global Follicular Lymphoma Treatment Revenue Forecast by Type (2023-2028)
Table 91. Global Follicular Lymphoma Treatment Revenue by Application (2017-2022)
Table 92. Global Follicular Lymphoma Treatment Revenue Forecast by Application (2023-2028)
Table 93. North America Follicular Lymphoma Treatment Revenue by Type (2017-2022) & (USD Million)
Table 94. North America Follicular Lymphoma Treatment Revenue by Type (2023-2028) & (USD Million)
Table 95. North America Follicular Lymphoma Treatment Revenue by Application (2017-2022) & (USD Million)
Table 96. North America Follicular Lymphoma Treatment Revenue by Application (2023-2028) & (USD Million)
Table 97. North America Follicular Lymphoma Treatment Revenue by Country (2017-2022) & (USD Million)
Table 98. North America Follicular Lymphoma Treatment Revenue by Country (2023-2028) & (USD Million)
Table 99. Europe Follicular Lymphoma Treatment Revenue by Type (2017-2022) & (USD Million)
Table 100. Europe Follicular Lymphoma Treatment Revenue by Type (2023-2028) & (USD Million)
Table 101. Europe Follicular Lymphoma Treatment Revenue by Application (2017-2022) & (USD Million)
Table 102. Europe Follicular Lymphoma Treatment Revenue by Application (2023-2028) & (USD Million)
Table 103. Europe Follicular Lymphoma Treatment Revenue by Country (2017-2022) & (USD Million)
Table 104. Europe Follicular Lymphoma Treatment Revenue by Country (2023-2028) & (USD Million)
Table 105. Asia-Pacific Follicular Lymphoma Treatment Revenue by Type (2017-2022) & (USD Million)
Table 106. Asia-Pacific Follicular Lymphoma Treatment Revenue by Type (2023-2028) & (USD Million)
Table 107. Asia-Pacific Follicular Lymphoma Treatment Revenue by Application (2017-2022) & (USD Million)
Table 108. Asia-Pacific Follicular Lymphoma Treatment Revenue by Application (2023-2028) & (USD Million)
Table 109. Asia-Pacific Follicular Lymphoma Treatment Revenue by Region (2017-2022) & (USD Million)
Table 110. Asia-Pacific Follicular Lymphoma Treatment Revenue by Region (2023-2028) & (USD Million)
Table 111. South America Follicular Lymphoma Treatment Revenue by Type (2017-2022) & (USD Million)
Table 112. South America Follicular Lymphoma Treatment Revenue by Type (2023-2028) & (USD Million)
Table 113. South America Follicular Lymphoma Treatment Revenue by Application (2017-2022) & (USD Million)
Table 114. South America Follicular Lymphoma Treatment Revenue by Application (2023-2028) & (USD Million)
Table 115. South America Follicular Lymphoma Treatment Revenue by Country (2017-2022) & (USD Million)
Table 116. South America Follicular Lymphoma Treatment Revenue by Country (2023-2028) & (USD Million)
Table 117. Middle East & Africa Follicular Lymphoma Treatment Revenue by Type (2017-2022) & (USD Million)
Table 118. Middle East & Africa Follicular Lymphoma Treatment Revenue by Type (2023-2028) & (USD Million)
Table 119. Middle East & Africa Follicular Lymphoma Treatment Revenue by Application (2017-2022) & (USD Million)
Table 120. Middle East & Africa Follicular Lymphoma Treatment Revenue by Application (2023-2028) & (USD Million)
Table 121. Middle East & Africa Follicular Lymphoma Treatment Revenue by Country (2017-2022) & (USD Million)
Table 122. Middle East & Africa Follicular Lymphoma Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Follicular Lymphoma Treatment Picture
Figure 2. Global Follicular Lymphoma Treatment Revenue Market Share by Type in 2021
Figure 3. Chemotherapy
Figure 4. Radiotherapy
Figure 5. Monoclonal Antibodies
Figure 6. Stem Cell Transplantation
Figure 7. Follicular Lymphoma Treatment Revenue Market Share by Application in 2021
Figure 8. Hospital Picture
Figure 9. Clinic Picture
Figure 10. Others Picture
Figure 11. Global Follicular Lymphoma Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 12. Global Follicular Lymphoma Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Follicular Lymphoma Treatment Revenue Market Share by Region (2017-2028)
Figure 14. Global Follicular Lymphoma Treatment Revenue Market Share by Region in 2021
Figure 15. North America Follicular Lymphoma Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Europe Follicular Lymphoma Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Asia-Pacific Follicular Lymphoma Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. South America Follicular Lymphoma Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Middle East and Africa Follicular Lymphoma Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Follicular Lymphoma Treatment Market Drivers
Figure 21. Follicular Lymphoma Treatment Market Restraints
Figure 22. Follicular Lymphoma Treatment Market Trends
Figure 23. Boehringer Ingelheim GmbH Recent Developments and Future Plans
Figure 24. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 25. Celgene Corporation Recent Developments and Future Plans
Figure 26. Celldex Therapeutics, Inc. Recent Developments and Future Plans
Figure 27. Celltrion, Inc. Recent Developments and Future Plans
Figure 28. Cellular Biomedicine Group, Inc. Recent Developments and Future Plans
Figure 29. Coherus BioSciences, Inc. Recent Developments and Future Plans
Figure 30. CTI BioPharma Corp. Recent Developments and Future Plans
Figure 31. Curis, Inc. Recent Developments and Future Plans
Figure 32. Dynavax Technologies Corporation Recent Developments and Future Plans
Figure 33. Eisai Recent Developments and Future Plans
Figure 34. EpiZyme, Inc. Recent Developments and Future Plans
Figure 35. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Figure 36. Genentech, Inc. Recent Developments and Future Plans
Figure 37. Gilead Sciences, Inc. Recent Developments and Future Plans
Figure 38. GlaxoSmithKline Plc Recent Developments and Future Plans
Figure 39. Hutchison MediPharma Limited Recent Developments and Future Plans
Figure 40. Immune Design Corp. Recent Developments and Future Plans
Figure 41. ImmunoGen, Inc. Recent Developments and Future Plans
Figure 42. Global Follicular Lymphoma Treatment Revenue Share by Players in 2021
Figure 43. Follicular Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 44. Global Top 3 Players Follicular Lymphoma Treatment Revenue Market Share in 2021
Figure 45. Global Top 10 Players Follicular Lymphoma Treatment Revenue Market Share in 2021
Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 47. Global Follicular Lymphoma Treatment Revenue Share by Type in 2021
Figure 48. Global Follicular Lymphoma Treatment Market Share Forecast by Type (2023-2028)
Figure 49. Global Follicular Lymphoma Treatment Revenue Share by Application in 2021
Figure 50. Global Follicular Lymphoma Treatment Market Share Forecast by Application (2023-2028)
Figure 51. North America Follicular Lymphoma Treatment Sales Market Share by Type (2017-2028)
Figure 52. North America Follicular Lymphoma Treatment Sales Market Share by Application (2017-2028)
Figure 53. North America Follicular Lymphoma Treatment Revenue Market Share by Country (2017-2028)
Figure 54. United States Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Canada Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Mexico Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Europe Follicular Lymphoma Treatment Sales Market Share by Type (2017-2028)
Figure 58. Europe Follicular Lymphoma Treatment Sales Market Share by Application (2017-2028)
Figure 59. Europe Follicular Lymphoma Treatment Revenue Market Share by Country (2017-2028)
Figure 60. Germany Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. France Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. United Kingdom Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Russia Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Italy Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Asia-Pacific Follicular Lymphoma Treatment Sales Market Share by Type (2017-2028)
Figure 66. Asia-Pacific Follicular Lymphoma Treatment Sales Market Share by Application (2017-2028)
Figure 67. Asia-Pacific Follicular Lymphoma Treatment Revenue Market Share by Region (2017-2028)
Figure 68. China Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Japan Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. South Korea Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. India Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Southeast Asia Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Australia Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South America Follicular Lymphoma Treatment Sales Market Share by Type (2017-2028)
Figure 75. South America Follicular Lymphoma Treatment Sales Market Share by Application (2017-2028)
Figure 76. South America Follicular Lymphoma Treatment Revenue Market Share by Country (2017-2028)
Figure 77. Brazil Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Argentina Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Middle East and Africa Follicular Lymphoma Treatment Sales Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Follicular Lymphoma Treatment Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Follicular Lymphoma Treatment Revenue Market Share by Country (2017-2028)
Figure 82. Turkey Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. Saudi Arabia Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. UAE Follicular Lymphoma Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. Methodology
Figure 86. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
